DK1725544T3 - 3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme - Google Patents

3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme

Info

Publication number
DK1725544T3
DK1725544T3 DK05724523T DK05724523T DK1725544T3 DK 1725544 T3 DK1725544 T3 DK 1725544T3 DK 05724523 T DK05724523 T DK 05724523T DK 05724523 T DK05724523 T DK 05724523T DK 1725544 T3 DK1725544 T3 DK 1725544T3
Authority
DK
Denmark
Prior art keywords
benzamides
triazol
heterocyclyl
inhibitors
aryl
Prior art date
Application number
DK05724523T
Other languages
English (en)
Inventor
Derek Cogan
Ming-Hong Hao
Victor Marc Kamhi
Craig A Miller
M R Netherton
Alan D Swinamer
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1725544T3 publication Critical patent/DK1725544T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
DK05724523T 2004-03-09 2005-03-04 3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme DK1725544T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55144504P 2004-03-09 2004-03-09
PCT/US2005/006997 WO2005090333A1 (en) 2004-03-09 2005-03-04 3-‘4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases

Publications (1)

Publication Number Publication Date
DK1725544T3 true DK1725544T3 (da) 2009-07-27

Family

ID=34962594

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05724523T DK1725544T3 (da) 2004-03-09 2005-03-04 3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme

Country Status (30)

Country Link
US (2) US7214802B2 (da)
EP (2) EP1887003A1 (da)
JP (1) JP4850824B2 (da)
KR (1) KR20060129077A (da)
CN (1) CN1930144A (da)
AR (1) AR048315A1 (da)
AT (1) ATE432273T1 (da)
AU (1) AU2005223738B2 (da)
BR (1) BRPI0508561A (da)
CA (1) CA2557856C (da)
CY (1) CY1109333T1 (da)
DE (1) DE602005014621D1 (da)
DK (1) DK1725544T3 (da)
EA (1) EA011634B1 (da)
EC (1) ECSP066833A (da)
ES (1) ES2327940T3 (da)
HR (1) HRP20090334T1 (da)
IL (1) IL177937A0 (da)
MY (1) MY143000A (da)
NO (1) NO20064120L (da)
NZ (1) NZ550148A (da)
PE (1) PE20051146A1 (da)
PL (1) PL1725544T3 (da)
PT (1) PT1725544E (da)
RS (1) RS50796B (da)
SI (1) SI1725544T1 (da)
TW (1) TW200602313A (da)
UA (1) UA85702C2 (da)
WO (1) WO2005090333A1 (da)
ZA (1) ZA200606177B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007121390A1 (en) * 2006-04-18 2007-10-25 Boehringer Ingelheim International Gmbh Process for making cytokine inhibiting compounds containing 4- and 5- imidazolyl rings and the intermediates thereof
CN101501023A (zh) 2006-07-07 2009-08-05 贝林格尔.英格海姆国际有限公司 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途
AU2007292155B2 (en) 2006-09-05 2012-11-01 Kyowa Kirin Co., Ltd. Imidazole derivative
CA2692379A1 (en) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
PE20090837A1 (es) * 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
WO2009070304A1 (en) 2007-11-27 2009-06-04 North Carolina State University Inhibition of biofilms in plants with imidazole derivatives
US9005643B2 (en) 2008-04-04 2015-04-14 North Carolina State University Inhibition of bacterial biofilms with imidazole-phenyl derivatives
US7897631B2 (en) * 2008-04-21 2011-03-01 North Carolina State University Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives
EP2324007B1 (en) * 2008-09-02 2012-08-15 NeuroSearch A/S Triazole derivatives and their use as nicotinic acetylcholine receptor modulators
AR073501A1 (es) 2008-09-08 2010-11-10 Boehringer Ingelheim Int Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
CN102227421A (zh) * 2008-09-29 2011-10-26 贝林格尔.英格海姆国际有限公司 抗增殖化合物
UY32147A (es) 2008-09-29 2010-04-30 Abbott Lab Derivados de indol y de indolina y métodos para usarlos
WO2010077603A1 (en) * 2008-12-08 2010-07-08 North Carolina State University Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives
EP2398797B1 (en) 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
US9221765B2 (en) 2009-06-10 2015-12-29 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
WO2011008312A2 (en) 2009-07-14 2011-01-20 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
WO2011084433A2 (en) 2009-12-17 2011-07-14 Abbott Laboratories Aza-bridged ring-fused indoles and indolines
WO2011084434A2 (en) 2009-12-17 2011-07-14 Abbott Laboratories Aza-ring fused indole and indoline derivatives
WO2011075487A1 (en) 2009-12-17 2011-06-23 Abbott Laboratories Bridgehead amine ring -fused indoles and indolines useful to treat neurodegenerative and neuropsychiatry disorders
AU2011204370B2 (en) 2010-01-07 2015-03-05 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
JP5871897B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジルトリアゾール
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
US8466181B2 (en) * 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN103476771B (zh) * 2011-01-28 2015-12-23 4Sc探索有限责任公司 用于治疗自身免疫炎症的IL17和IFN-γ抑制
BR112013019256B1 (pt) * 2011-01-28 2021-10-13 4Sc Discovery Gmbh Inibidores de il-17 e ifn-gama, e seu uso
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8859549B2 (en) 2011-05-13 2014-10-14 Abbvie, Inc. Potassium channel modulators
JP6054869B2 (ja) 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
EP3066083B1 (de) * 2013-11-05 2019-10-30 Bayer Animal Health GmbH Neue verbindungen zur bekämpfung von arthropoden
WO2017108737A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
CA3052466A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2019169193A1 (en) 2018-03-01 2019-09-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
JP7391055B2 (ja) * 2018-07-04 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１４２アゴニストとしてのトリアゾールベンズアミド誘導体
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
PE20221010A1 (es) 2019-08-14 2022-06-15 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
WO2022188792A1 (zh) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
TW202329942A (zh) 2021-11-19 2023-08-01 日商日本曹達股份有限公司 2-烷硫-1-咪唑乙酮化合物之製造方法
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
EP0906307B1 (en) * 1996-06-10 2005-04-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
JP4385414B2 (ja) * 1997-10-13 2009-12-16 アステラス製薬株式会社 アミド若しくはアミン誘導体
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
JP2002510679A (ja) * 1998-04-08 2002-04-09 アボット・ラボラトリーズ ピラゾールサイトカイン産生阻害剤
CA2332957A1 (en) * 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
US6615065B1 (en) 1998-10-13 2003-09-02 Somanetics Corporation Multi-channel non-invasive tissue oximeter
EP1123287B1 (en) 1998-10-23 2003-07-30 Dow AgroSciences LLC Insecticidal 3- (substituted pyridyl) -1, 2, 4-triazoles
US6451820B1 (en) * 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
US6498423B1 (en) 2001-06-27 2002-12-24 Welch Allyn, Inc. Lamp thermal control by directed air flow
WO2003022820A1 (en) 2001-09-06 2003-03-20 Bristol-Myers Squibb Pharma Company. Heteroaromatic substituted cyclopropane as corticotropin releasing hormone
ES2367422T3 (es) 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
WO2003063781A2 (en) 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7396935B2 (en) * 2003-05-01 2008-07-08 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
SI1725544T1 (sl) 2009-10-31
AU2005223738A1 (en) 2005-09-29
CA2557856C (en) 2010-06-29
EA011634B1 (ru) 2009-04-28
ES2327940T3 (es) 2009-11-05
PL1725544T3 (pl) 2009-10-30
NZ550148A (en) 2010-07-30
WO2005090333A8 (en) 2006-08-24
EP1887003A1 (en) 2008-02-13
JP2007528395A (ja) 2007-10-11
DE602005014621D1 (de) 2009-07-09
PT1725544E (pt) 2009-07-02
US7514458B2 (en) 2009-04-07
ZA200606177B (en) 2008-12-31
EA200601571A1 (ru) 2007-02-27
PE20051146A1 (es) 2006-02-02
ATE432273T1 (de) 2009-06-15
NO20064120L (no) 2006-09-26
ECSP066833A (es) 2006-11-24
KR20060129077A (ko) 2006-12-14
CN1930144A (zh) 2007-03-14
HRP20090334T1 (en) 2009-07-31
EP1725544A1 (en) 2006-11-29
US20070142371A1 (en) 2007-06-21
CY1109333T1 (el) 2014-07-02
MY143000A (en) 2011-02-14
BRPI0508561A (pt) 2007-08-14
JP4850824B2 (ja) 2012-01-11
RS50796B (sr) 2010-08-31
WO2005090333A1 (en) 2005-09-29
UA85702C2 (ru) 2009-02-25
US20060079519A1 (en) 2006-04-13
TW200602313A (en) 2006-01-16
AU2005223738B2 (en) 2011-08-11
IL177937A0 (en) 2006-12-31
AR048315A1 (es) 2006-04-19
CA2557856A1 (en) 2005-09-29
US7214802B2 (en) 2007-05-08
EP1725544B1 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
DK1725544T3 (da) 3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme
LTC1907382I2 (lt) Nitrokatechnolio dariniai, kaip COMT inhibitoriai
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
CY2013014I1 (el) Εναντιομερικως καθαρες αμινοετεροαρυλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2019683T4 (da) Indgivelse af vækstfaktorer til behandling af CNS-lidelser
IL182212A0 (en) Indazolone derivatives as 11b-hsd1 inhibitors
IL180736A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
NL1029015A1 (nl) Therapeutische verbindingen.
WO2010038086A3 (en) P38 map kinase inhibitors
IL180187A (en) Composition for treating inflammatory disorders
DK1704145T3 (da) Selektive kinaseinhibitorer
DE602005000849D1 (de) Kältekammer
DK1871380T3 (da) Kombineret anvendelse af prostaglandinforbindelse og protonpumpeinhibitor til behandlingen af gastrointestinale lidelser
DK1740569T3 (da) Imidazol-derivater som TAFla-inhibitorer
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
DE602005017957D1 (de) Regelungsverfahren für Wärmepumpen
DK1713805T3 (da) Kinaseinhibitorer
DK1801108T3 (da) Morpholinforbindelser til behandling af inflammationer.
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
ITTO20050018A1 (it) Struttura per la disposizione di cuscinetti.
FR2877958B1 (fr) Nouvelle structure de plancher en bois
ITRM20040285A1 (it) Piattelli per la fabbricazione di crepes.